Bone, joint, and mobility is the main area connected here, and any felt benefit should be read together with the human evidence base.
Representative tier calculated from paper evidence that passed the collection audit.
The representative ingredient tier is calculated from these target-level evidence groups.
10 new papers were added in this period. No new risk signal was identified.
Standalone side-effect signals and combination cautions are listed separately.
Paper IDs and full lists are private. Only study types and summaries are shown.
Focus group discussions revealed how previous and anticipated negative interactions with physicians and skepticism about the healthcare system have alienated young Black MSM from the health care system and created significant barriers to PrEP.
Results depict an HA outbreak of multiple HAV strains, within a cross-European population, that was particularly driven by transmission between non-immune MSM engaging in high-risk sexual behaviour.
As a Generally Recognized As Safe (GRAS) approved substance, MSM is well-tolerated by most individuals at dosages of up to four grams daily, with few known and mild side effects.
There was no evidence of risk compensation among HIV-uninfected MSM in this clinical trial and monitoring for risk compensation should continue now that preexposure prophylaxis has been shown to be efficacious in MSM and other populations.
While some MSM engaging in chemsex and SDU appeared content with these behaviours, the association with life satisfaction and sexual self-efficacy indicates psychosocial support is needed for some, and the importance of promoting harm reduction among this popu
Among MSM on PrEP, there were decreases in condom use, and a higher prevalence of STIs during PrEP use compared to prior to PrEP initiation, and there was no change in number of sexual partners or reporting HIV-positive or HIV-negative partners.